Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

AbbVie Announces Four New Global Research Collaborations Focused on Advancing Next-Gen Science

Monday, January 9, 2017   (0 Comments)
Posted by: Kate Oesterle
Share |
Jan 09, 2017

 

- Collaborations will focus on key therapeutic areas, including oncology and immunology

 

NORTH CHICAGO, Ill., Jan. 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced four new collaborations and investments with leading healthcare innovators to advance early-stage research in key therapeutic areas such as oncology and immunology. AbbVie is committed to investing in and developing transformational science and technologies to advance the next-generation of therapies across its robust pipeline in key therapeutic areas.  With more than 50 compounds in clinical development, AbbVie's pipeline spans significant areas of medical need including oncology, immunology, neuroscience and virology.

"We can develop tomorrow's most important therapies by investing in today's leading technologies and scientific achievements," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "Combining the strengths of AbbVie's discovery and development expertise and novel research from external partners will accelerate the pace of innovation into new medicines for the next-generation of medical treatment."

 

Read full article.


Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal